dc.contributor.author | Zeidan, AM | |
dc.contributor.author | Boss, IW | |
dc.contributor.author | Beach, CL | |
dc.contributor.author | Copeland, WB | |
dc.contributor.author | Thompson, EG | |
dc.contributor.author | Fox, BA | |
dc.contributor.author | Hasle, VE | |
dc.contributor.author | Hellmann, A | |
dc.contributor.author | Taussig, D | |
dc.contributor.author | Tormo, M | |
dc.contributor.author | Voso, MT | |
dc.contributor.author | Cavenagh, J | |
dc.contributor.author | O'Connor, T | |
dc.contributor.author | Previtali, A | |
dc.contributor.author | Rose, S | |
dc.contributor.author | Silverman, LR | |
dc.date.accessioned | 2022-05-09T14:46:20Z | |
dc.date.available | 2022-05-09T14:46:20Z | |
dc.date.issued | 2021-12-21 | |
dc.identifier.citation | Blood advances, 2021 | en |
dc.identifier.issn | 2473-9529 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5115 | |
dc.identifier.eissn | 2473-9537 | en_US |
dc.identifier.eissn | 2473-9537 | |
dc.identifier.doi | 10.1182/bloodadvances.2021006138 | en_US |
dc.identifier.doi | 10.1182/bloodadvances.2021006138 | |
dc.description.abstract | Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to first-line therapy with azacitidine 75 mg/m2 on days 1-7 with (Arm A, n= 64) or without (Arm B, n=65) durvalumab 1500 mg on day 1 every 4 weeks. Overall response rate (complete response [CR] + CR with incomplete blood recovery [CRi]) was similar in both arms (Arm A, 31.3%; Arm B, 35.4%), as were overall survival (A, 13.0 months; B, 14.4 months) and duration of response (A, 24.6 weeks; B, 51.7 weeks; P=0.0765). No new safety signals emerged with combination treatment. The most frequently reported treatment-emergent adverse events were constipation (Arm A, 57.8%; Arm B, 53.2%) and thrombocytopenia (A, 42.2%; B, 45.2%). DNA methylation, mutational status, and PD-L1 expression were not associated with response to treatment. In this study, first-line combination therapy with durvalumab and azacitidine in older patients with AML was feasible, but did not improve clinical efficacy compared with azacitidine alone. ClinicalTrials.gov: NCT02775903. | en_US |
dc.format | Print-Electronic | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en |
dc.title | Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia. | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-11-24 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1182/bloodadvances.2021006138 | en |
rioxxterms.licenseref.startdate | 2021-12-21 | |
dc.relation.isPartOf | Blood advances | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia/Acute Leukaemia (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Acute Leukaemia | |
dc.contributor.icrauthor | Taussig, David | |